ArticlePediatric nephrology (Berlin, Germany)2026
Correlation of serum beta-2 microglobulin with hemodialysis prescription and comorbid factors in children undergoing chronic hemodialysis.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemodialysis (HD) is a method of kidney replacement therapy designed to remove uremic toxins from the body. Beta-2 microglobulin (beta-2 MG) is a middle molecule not yet effectively removed by conventional low-flux dialysis membranes and may contribute to long-term complications in chronic HD patients. While well-studied in adults, data in pediatric populations are limited. This study evaluated beta-2 MG levels before and after HD in children and assessed associations with dialysis prescription parameters and cardiovascular comorbidities.
methodsA cross-sectional study was conducted from June to July 2024 at the Kiara Children's Dialysis Unit, Rumah Sakit Umum Pusat Nasional (RSUPN) Cipto Mangunkusumo, Indonesia. Pre- and post-HD beta-2 MG levels were measured. Dialysis prescriptions, laboratory values, and cardiovascular parameters were recorded and analyzed for correlations with beta-2 MG levels and reduction ratios.
resultsThe study involved 38 subjects, of whom 22 (57.9%) were male, with an average age of 13.2 ± 2.9 years. Most patients received HD twice weekly. Pre-HD beta-2 MG levels were elevated in all patients. Synthetic-based high-flux dialyzers were significantly associated with greater beta-2 MG reduction ratios compared to cellulose-based low-flux membranes (r = 0.716; p = 0.000). No significant correlations were found between beta-2 MG levels and other HD parameters, laboratory markers, or cardiovascular outcomes.
conclusionsSynthetic-based high-flux dialyzers were associated with improved beta-2 MG clearance in pediatric HD patients, though pre-HD levels were comparable across membrane types. Further longitudinal studies are warranted to determine the clinical significance of beta-2 MG reduction and guide dialysis optimization in children.
Indexed as
Identifiers
41247391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.